Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Elanco's Long-Acting Transdermal Buprenorphine for Cats Gains FDA Approval

The FDA has approved Elanco Animal Health Inc (NYSE:ELAN) Zorbium (buprenorphine transdermal solution) to control postoperative pain associated with surgical procedures in cats.

  • The approval expands Elanco's pain management offerings for veterinary practices.
  • Zorbium provides up to four days of pain control from a single transdermal dose without relying upon owners to administer an opioid after discharge and the need for repeat injections.
  • Related: Elanco To Lay Off 20% Senior Management In Organizational Restructure. 
  • Consistent pain control reassures cat owners and reduces the challenges of administering pain medications at home.
  • Zorbium is for topical application in cats only. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: ELAN shares closed at $26.83 on Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.